Auvelity (dextromethorphan/bupropion)

Auvelity is a once-daily pill that combines dextromethorphan, the cough syrup ingredient, with bupropion, which most people know as Wellbutrin. It got FDA approval in 2022 for major depression and was marketed as the first novel mechanism in antidepressants in decades. Real claim or marketing? Honestly, both. It does something different. Whether it does it dramatically better than what we already had is the actual question, and the honest answer is more complicated than the ads make it sound.

The mechanism story: dextromethorphan is an NMDA receptor antagonist (the same broad class as ketamine, meaning it modulates the glutamate system, which is the brain’s main excitatory wiring and a relatively new target for antidepressants). The bupropion is in there for two reasons. First, bupropion blocks a specific liver enzyme that would otherwise destroy the dextromethorphan before it could reach the brain at meaningful levels. Second, bupropion is a real antidepressant in its own right, the dopamine-and-norepinephrine kind, the one that’s cleaner on sexual side effects and doesn’t cause weight gain. So you get NMDA modulation plus standard antidepressant activity in one capsule. The combination is the point.

What the trials showed

The pivotal trials tested it two ways, one against bupropion alone and one against placebo, and Auvelity beat both. The response was faster, with some patients showing benefit within a week or two, and the magnitude of effect was modest but real. So the claim that it beats bupropion is true, and it clears placebo too.

The trickier claim is whether it beats anything else. There’s no head-to-head trial of Auvelity against an SSRI (selective serotonin reuptake inhibitor, the modern first-line antidepressant class, things like Lexapro and Zoloft) at an adequate dose, or against an SNRI (serotonin-norepinephrine reuptake inhibitor, the broader-acting cousin class like Effexor and Cymbalta), or against ketamine. So the marketing claim that this is a fundamentally faster antidepressant is true relative to bupropion alone, but we don’t have great data on whether it’s actually faster than just starting Lexapro or Effexor, which is what most patients are starting with anyway. That’s a meaningful gap in the evidence.

What it feels like to take

Onset for the antidepressant effect is described as faster than SSRIs. Some patients report a lift within the first week or two. SSRIs typically take four to eight weeks to do their thing, which is part of what makes them frustrating to start. For patients who are deep in it and need to feel something soon, that timeline difference matters, even if the trial data comparing the two head-to-head doesn’t actually exist.

Side effects are mostly what you’d expect from bupropion plus a little extra from the dextromethorphan. Dry mouth. Some nausea early on. A subset of patients report dizziness. A smaller subset report a mild dissociative feeling for an hour or two after the dose, particularly the morning one, where the world feels a half-step removed for a while. Not full dissociation like Spravato. Just a slight sense of being one inch behind your own eyes for an hour. Most patients adapt within the first couple of weeks, some don’t, and the ones who don’t usually want off the drug, which is fair.

Sexual side effects: less than SSRIs, mostly because of the bupropion component, which is the cleanest antidepressant available for sexual function and is one of the few that doesn’t tank libido or make finishing harder.

Weight: neutral to slightly negative, again because of the bupropion. Patients who gained weight on an SSRI sometimes lose a few pounds on Auvelity, which is worth knowing but not the reason to choose it.

Activation: yes. Like bupropion, it can make you slightly wired, slightly jittery, particularly in the first couple of weeks. For patients with significant anxiety mixed in with the depression, this can be a problem, because adding wired-and-jittery on top of already-anxious is not what they came in for.

The cost reality

List price is around $1,000 a month. With commercial insurance, after prior authorization and the manufacturer copay card, most patients can get it for $10 to $50 a month. Without insurance or with restrictive plans, this gets expensive fast, and it’s hard to justify when generic bupropion is fifteen dollars a month and an SSRI is similar.

Some clinicians have been combining bupropion with dextromethorphan separately to mimic Auvelity for a fraction of the cost. The science is roughly sound. The pharmacokinetics aren’t identical because the Auvelity formulation includes the bupropion specifically dosed and timed to block the liver enzymes effectively, and is dose-balanced. It’s a workaround for cash-pay patients, but it’s not the same thing. Doable, not clean.

What’s nice to hear about this one

For the right patient, Auvelity is one of the cleaner additions to the antidepressant menu in years. The pattern: picture a guy who’s been on Lexapro for two years, then Wellbutrin for a year, then both together at the top of the standard doses, getting maybe sixty percent of the way out of the depression and stalling. He’s functional but flat. He has a kid on the way and his wife has told him she wants him to actually be present, not just present. Switch to Auvelity. First week he reports feeling slightly wired and slightly off, like a low-grade buzz, which usually settles. By week three he says he feels like himself for the first time in three years. Not euphoric, just himself. Ten months in, he’s still on it, his daughter is six months old, he says he’s been there for her in a way he wasn’t sure he was going to manage. That arc is real. Whether the Auvelity made the difference, whether time made the difference, whether going up on plain Wellbutrin would have done the same thing… honestly, hard to say with certainty in any one patient, but he thinks it did, and the trials say there’s a real signal there.

Some patients report a lift within the first week or two. For patients who are deep in it, that timeline matters.

Where it fits in the algorithm

For most prescribers, Auvelity is a second or third line option. SSRIs first, because most patients respond and the math is cheaper. Bupropion alone or an SNRI second, depending on the symptom profile, with bupropion being the cleaner choice if sexual side effects or weight gain were issues with the SSRI. Auvelity if those haven’t gotten the patient there, particularly if the patient already responded partially to bupropion and the goal is to push further without stacking another full antidepressant on top.

Patients with active anxiety, careful. Patients with seizure history, no (same reason as bupropion, the seizure threshold thing). Patients on other serotonergic agents, check carefully for serotonin syndrome risk, because dextromethorphan plays into that pathway and stacking it with an SSRI or an SNRI can cause problems if it isn’t watched.

On the autonomy piece

Patients who saw the commercials and want Auvelity by name aren’t wrong to want it, they’re just often not the patients it’s the best fit for. If a patient hasn’t tried an SSRI at an adequate dose for an adequate trial yet, starting with Auvelity is skipping a step that usually works, and most insurance won’t cover it anyway. If a patient has tried the cheaper stuff and wants this one next, fine, the data supports it. I’m not a gatekeeper. The take is just that the order of operations exists for a reason, and starting with the most expensive option because the ad was compelling is usually not the right move. Disapproving yes is the most resistance you’ll get from me. The choice is yours.

The deeper question Auvelity raises

The actually interesting thing about this drug isn’t whether it works, it’s what it tells us about the next decade of antidepressants. The glutamate-system target is real… ketamine showed that, Spravato showed that. Auvelity is the first oral once-a-day pill that hits that system in any meaningful way, which is a real piece of progress even if the magnitude of effect is modest. The pipeline behind it has more compounds in that same family, and within the next five years the menu is probably going to look meaningfully different than the SSRI-and-SNRI dominated landscape that the field has been stuck in since the 90s. That’s a good thing. The SSRI era has been a long time, and the patients who didn’t respond to that whole class deserve more options.

Bottom line

Auvelity is a real medication that does something a little different than the standard antidepressants. It probably works faster than its components alone. It’s expensive enough that for most patients the cheaper options come first. For the right patient, particularly somebody who responded partially to bupropion and needs more, it can move the needle. The marketing oversells the novelty. The drug itself is fine, which is honestly the most you can say about most things in this category.

Sources

1. Tabuteau H, Jones A, Anderson A, et al. Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial. Am J Psychiatry. 2022;179(7):490-499. PMID 35582785.
2. Iosifescu DV, Jones A, O’Gorman C, et al. Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry. 2022;83(4):21m14345. PMID 35649167.
3. Stahl SM. Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity. CNS Spectr. 2019;24(5):461-466. PMID 31566163.